Author Archives: Marisa Wexler MS

Onpattro Now Will Be Reimbursed for Most Patients in Canada

Onpattro (patisiran) is now reimbursed for patients with familial amyloid polyneuropathy (FAP) living across most regions of Canada, according to Alnylam Pharmaceuticals, the therapy’s developer. The announcement comes following a positive recommendation for reimbursement from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut…

Depression, Anxiety Common With FAP, Patient Survey Finds

Challenges with mental health often follow a person being told that they carry a mutation that causes familial amyloid polyneuropathy (FAP), a rare and progressive disease of adulthood, a study reports. “These results highlight the burden of [FAP] for patients and their relatives. Patients, carriers and their relatives and…

FDA to Decide on Vutrisiran’s Possible Approval by April 2022

Alnylam Pharmaceuticals’ application for the approval of vutrisiran, its investigational therapy for familial amyloid polyneuropathy (FAP), is being reviewed by the U.S. Food and Drug Administration (FDA), with a decision expected by April 14 of next year. The agency has indicated that it is not currently planning…

Amyl Raises Funds to Develop Therapies for Amyloidosis

Amyl Therapeutics has raised €18.3 million — about $22.2 million — to develop its ClariTY technology platform to advance therapeutic candidates for familial amyloid polyneuropathy (FAP) and other forms of amyloidosis. “The ClariTY platform offers the unique opportunity to generate therapeutic candidates able to target all amyloid fibril…

#AANAM – Onpattro Reduced Nervous System Damage in Trial

Editor’s note: The FAP News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read more stories from the conference. Treatment with Onpattro (patisiran) lessened signs of nervous system damage in people with familial amyloid polyneuropathy (FAP), new clinical…